Finding effective treatments and a cure for MND
People living with MND now have more opportunities to participate in research or clinical trials throughout Australia. It is proof of the accelerating progress we are making to end MND.
FightMND have invested in 11 clinical trials for Australian patients and 17 drug development projects. It’s projects like these that will help us find more effective treatments and ultimately a cure.
Below you will find a list of the clinical trials, drug development projects and impact grants we’ve invested in since 2016.
Drug development projects
Drug Development projects are focused on advancing promising new drugs or therapies through the final stages of testing in preparation for their assessment in clinical trials with MND patients.
- SMN2 SPLICE-SWITCHING OLIGONUCLEOTIDE THERAPY DEVELOPMENT FOR MND (A/Prof Brad Turner)
- COMPLEMENT C3A RECEPTOR MODULATORS AS DISEASEMODIFYING DRUGS FOR MND (Prof Trent Woodruff)
- PRECLINICAL DEVELOPMENT OF A SOD1 GENETIC THERAPY IN SPORADIC MND (Prof Steve Wilton, Prof Anthony Akkari, Dr Loren Flynn)
- DEVELOPMENT OF A TDP-43-TARGETING GENE THERAPY FOR MND (Prof Roger Chung)
- COMBINATION THERAPY TO IMPROVE CuATSM OUTCOMES IN MND (Prof Justin Yerbury)
- DEVELOPING M102 TO TREAT MND (Dr Ning Shan)
- MODULATING ACTIN DYNAMICS IN MND AS A NOVEL THERAPEUTIC APPROACH (Prof Julie Atkin)
- PROGRESSION OF THE C5A ANTAGONIST PMX205 TO CLINICAL TRIALS FOR MND (A/Prof Trent Woodruff)
- A NOVEL EPHRIN RECEPTOR A4-FC FUSION PROTEIN FOR THE TREATMENT OF SPORADIC MND (Prof Perry Bartlett)
- TARGETING THE METABOLISM OF GLYCOSPHINGOLIPIDS AS A NOVEL THERAPEUTIC STRATEGY FOR MND (A/Prof Bradley Turner)
- TARGETING A DEREGULATED COPPER-IRON AXIS TO TREAT SPORADIC MND: A COMBINATION TREATMENT STRATEGY (A/Prof Peter Crouch)
- 1 – NOVEL THERAPEUTICS TARGETING NEURONAL TRANSPORT PATHWAYS IN MND, 2 – THERAPEUTICS BASED ON THE PROTECTIVE ACTIVITY OF PROTEIN DISULPHIDE ISOMERASE IN MND (A/Prof Atkin)
- PRECLINICAL DEVELOPMENT OF NEUROPEPTIDE Y FOR THE TREATMENT OF MND (Prof Tracey Dickson)
To accelerate the development of effective therapies for MND, FightMND IMProving and ACcelerating Translation (IMPACT) grants support projects focused on overcoming one or more key barriers preventing the advancement of potential treatments through to clinical trial.
- DEVELOPMENT OF A DOSEESCALATABLE AAV DELIVERY SYSTEM FOR MND GENE THERAPIES (Prof Roger Chung)
- USING 3D SPINAL CORD ORGANOIDS TO MODEL OLIGODENDROCYTE NEUROTOXICITY IN MND (Dr Samantha Barton)
- LIPIDOMIC SIGNATURES IN BLOOD AS A NOVEL BIOMARKER FOR MND (Dr Sophia Luikinga)
- PRION-LIKE STRAINS OF TDP-43 AGGREGATES IN MND (Prof Justin Yerbury)
- USING BIOMARKERS TO ADDRESS MND HETEROGENEITY AND IMPROVE DETECTION TO BENEFIT CLINICAL TRIALS (Dr Mary-Louise Rogers)
- IDENTIFYING BIOMARKERS FROM EXTRACELLULAR VESICLES FOR EARLY DETECTION, DISEASE PROGRESSION AND THERAPEUTIC EFFICIENCY IN MND (Prof Aaron Russell)
- DEFINING AN ELECTRICAL SIGNATURE OF SPORADIC MND, AND DEVELOPING A DRUG SCREENING TECHNOLOGY AND NOVEL THERAPY (A/Prof Lezanne Ooi)
- DEVELOPING BLOOD-BRAIN BARRIER PENETRATING PEPTIDES (Dr Fazel Shabanpoor)
Other funded research initiatives
The aim of this program is to rapidly find potential treatments for Motor Neurone Disease. We are using award-winning technology allowing us to grow motor neurones from patient cells.